• David has over 18 years experience in the field of molecular cardiology both in academia and pharma.

​

• David received his BSc from Carnegie Mellon University (USA) and PhD from Rutgers Medical School (USA) before going on to pursue academic postdoctoral fellowships at Harvard Medical School/Boston Children´s Hospital/Department of Pediatric Cardiology (USA) and then at the Max Planck Institute of Heart and Lung Research (Germany).

​

• Upon completion of his academic fellowships, David transitioned to the pharmaceutical industry first at AstraZeneca (Sweden) and then Novo Nordisk (Denmark) where he identified and developed heart failure targets and therapeutics.

​

• From 2019 - 2022, David was Assistant Professor (tenure track) at the Chinese University of Hong Kong (CUHK)/Hong Kong Children’s Hospital (Hong Kong, SAR, PRC) in the Faculty of Medicine, Department of Medicine and Therapeutics. While at CUHK, David received 4.0M HKD (510K USD) in funding and was a grant recipient of internationally reviewed awards from both the Hong Kong Research Grants Council (RGC) and Hong Kong Health and Medical Research Fund (HMRF).

​

• In 2022, David founded GenKardia Inc., where he currently serves full-time as CEO.